Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
Nishio, Makoto, Murakami, Haruyasu, Ohe, Yuichiro, Hida, Toyoaki, Sakai, Hiroshi, Kasahara, Kazuo, Imamura, Fumio, Baba, Tomohisa, Kubota, Kaoru, Hosomi, Yukio, Shimokawa, Tsuneo, Hayashi, Hidetoshi,Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-019-00732-4
Date:
February, 2019
File:
PDF, 578 KB
english, 2019